Biomarker testing for personalized, first-line therapy in advanced nonsquamous non-small cell lung cancer patients in the real world setting in Japan: a retrospective, multicenter, observational study (the BRAVE study)

BACKGROUND: Molecular diagnostic testing is necessary to guide optimal first-line treatment. The number of patients who receive first-line treatment based on biomarker analysis in Japan is unknown. We aimed to determine the proportion of nonsquamous non-small cell lung cancer (NSCLC) patients for wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Junichi, Masago, Katsuhiro, Saito, Haruhiro, Nishino, Kazumi, Kurata, Takayasu, Itoh, Yohji, Yoshimura, Yoko, Yabuki, Yutaka, Dosaka-Akita, Hirotoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036489/
https://www.ncbi.nlm.nih.gov/pubmed/32127924
http://dx.doi.org/10.1177/1758835920904522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036489/
https://www.ncbi.nlm.nih.gov/pubmed/32127924
http://dx.doi.org/10.1177/1758835920904522

Ejemplares similares